Loading
POLA2 (DNA polymerase alpha subunit B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.
Accessory subunit of the DNA polymerase alpha complex (also known as the alpha DNA polymerase-primase complex) which plays an essential role in the initiation of DNA synthesis. During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of a catalytic subunit POLA1, an accessory subunit POLA2 and two primase subunits, the catalytic subunit PRIM1 and the regulatory subunit PRIM2) is recruited to DNA at the replicative forks via direct interactions with MCM10 and WDHD1. The primase subunit of the polymerase alpha complex initiates DNA synthesis by oligomerising short RNA primers on both leading and lagging strands.
Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes literature 0.85, affected pathway 0.61, genetic association 0.06, clinical 0.99).
In plain words · POLA2 (DNA polymerase alpha subunit B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.
POLA2 (DNA polymerase alpha subunit B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.
Accessory subunit of the DNA polymerase alpha complex (also known as the alpha DNA polymerase-primase complex) which plays an essential role in the initiation of DNA synthesis.
No product in this corpus aims at POLA2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA lists POLA2 among essential proteins and finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA POLA2: RNA low tissue specificity; high antibody staining in 11 normal tissues; highest cancer staining melanoma (4 of 11 high). Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Lymphoma, Lung cancer (all types), Myeloid neoplasms, Breast cancer (all types), Ovarian cancer); Open Targets associates it with 10 specific cancer types at or above 0.5 (non-small cell lung carcinoma, acute lymphoblastic leukemia, acute myeloid leukemia, B-cell chronic lymphocytic leukemia, exocrine pancreatic carcinoma, ovarian carcinoma and more). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas POLA2 tissue; Open Targets ENSG00000014138 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Collins K.L. et al, EMBO J, 1993, "The role of the 70 kDa subunit of human DNA polymerase alpha in DNA replication". Source.
Sources: HGNC HGNC:30073 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q14181 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000014138 (association with cancer (MONDO_0004992) 0.71; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.60, ovarian cancer 0.58, acute myeloid leukaemia 0.59, acute lymphoblastic leukaemia 0.60, B-cell chronic lymphocytic leukaemia 0.59, non-Hodgkin lymphoma 0.60 (GraphQL API, CC0))
Accessory subunit of the DNA polymerase alpha complex (also known as the alpha DNA polymerase-primase complex) which plays an essential role in the initiation of DNA synthesis. During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of a catalytic subunit POLA1, an accessory subunit POLA2 and two primase subunits, the catalytic subunit PRIM1 and the regulatory subunit PRIM2) is recruited to DNA at the replicative forks via direct interactions with MCM10 and WDHD1. The primase subunit of the polymerase alpha complex initiates DNA synthesis by oligomerising short RNA primers on both leading and lagging strands. These primers are initially extended by the polymerase alpha catalytic subunit and subsequently transferred to polymerase delta and polymerase epsilon for processive synthesis on the lagging and leading strand, respectively. Location: Nucleus (UniProt). Locus 11q13.1 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
Medium: Adipose tissue, Adrenal gland, Appendix, Bone marrow, Breast, Bronchus, Caudate, Cervix.
Medium only: breast cancer, cervical cancer, colorectal cancer, endometrial cancer.
HPA POLA2 tissue · HPA POLA2 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"POLA2" OR ABSTRACT:"POLA2" OR TITLE:"DNA polymerase alpha 2, accessory subunit" OR ABSTRACT:"DNA polymerase alpha 2, accessory subunit" OR TITLE:"DNA polymerase alpha subunit B" OR ABSTRACT:"DNA polymerase alpha subunit B" OR TITLE:"FLJ21662" OR ABSTRACT:"FLJ21662") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about POLA2, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.